Ivy Brain Tumor Center and Karyopharm Therapeutics Collaborate to Develop Tissue-Based Clinical Trial for Brain Cancer

The Ivy Brain Tumor Center will employ Karyopharm’s first-in-class oral Selective Inhibitor of Nuclear Export (SINE) compound, selinexor, in combination with other new-in-class drugs, as a dual-drug experimental therapy for adult glioblastoma.

New Study Makes Important Step Toward Treatment of Deadly Brain Cancer

A new Ivy Brain Tumor Center study finds that recently-approved drug ribociclib may be an important part of treatment for glioblastoma, one of the deadliest cancers in the world.

Close Menu